Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
| ▸ | MMP8 | P22894 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147656 | 0.84 | SLC6A2 (0.52) | SMN1; SMN2HIF1ASLC6A2TAAR1CYP3A4 | |
| SCHEMBL517462 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2HIF1ASLC6A2TAAR1CYP3A4 | |
| SCHEMBL28727407 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2HIF1ASLC6A2TAAR1CYP3A4 | |
| SCHEMBL28246706 | 0.83 | HIF1A (0.55) | SMN1; SMN2HIF1ASLC6A2TAAR1CYP3A4 | |
| SCHEMBL8759 | 0.83 | SLC6A2 (0.56) | SMN1; SMN2HIF1ASLC6A2TAAR1CYP3A4 | |
| SCHEMBL6552350 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1ASLC6A2TAAR1CYP3A4 | |
| SCHEMBL9784950 | 0.81 | TRPA1 (0.48) | SMN1; SMN2HIF1ASLC6A2TAAR1CYP3A4 | |
| Hydrochloric Acid SCHEMBL3136989 | 0.81 | SLC6A2 (0.54) | SMN1; SMN2HIF1ASLC6A2TAAR1CYP3A4 | |
| SCHEMBL2175542 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2HIF1ASLC6A2TAAR1CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL11617477 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2HIF1ASLC6A2TAAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| US-6737544-B1 | HEATING ABOVE MELTING POINT | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-18 | — | — | US | disclosed |
| US-6639070-B1 | 4-substituted 1,3,4-oxadiazines; herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-28 | — | — | US | disclosed |
| EP-1187819-B1 | N-SUBSTITUTED PERHYDRO DIAZINE | BASF AG (DE) | 2003-07-23 | — | — | EP | disclosed |
| EP-1315733-A2 | METHOD FOR PRODUCING ANELLATED TETRAHYDRO-[1H]-TRIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-04 | — | — | EP | disclosed |
| EP-1218350-A1 | 1-ARYL-1,3-DIHYDRO-IMIDAZOL-2-(THI)ONE DERIVATIVES, PRODUCTION OF SAID COMPOUND AND USE AS A DESSICATING/DEFOLIATING AGENT FOR PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-03 | — | — | EP | disclosed |
| US-6380259-B2 | SUCH AS CHRONIC BRONCHITIS, COMPOUNDS SUCH AS 4-(5-(4-(AMINOIMINOMETHYL)PHENOXY)PENTOXY)-2-HYDROXY-N,N-BIS-( 1-METHYLETHYL)BENZAMIDE (Z)-2-BUTENEDIOATE | NOVARTIS AG (CH) | 2002-04-30 | — | — | US | disclosed |
| EP-1187820-A1 | SUBSTITUTED UREAS | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-20 | — | — | EP | disclosed |
| EP-1187819-A1 | N-SUBSTITUTED PERHYDRO DIAZINE | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-20 | — | — | EP | disclosed |
| WO-2002020531-A2 | METHOD FOR PRODUCING ANELLATED TETRAHYDRO-[1H]-TRIAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-14 | — | — | WO | disclosed |
| US-5488160-A | LEUKOTRIENE B4 RECEPTOR ANTAGONIST AS ANTIINFLAMMATORY AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-01-30 | — | — | US | disclosed |
| US-5455274-A | Leukotriene antagonists; treating rheumatoid arthritis | CIBA-GEIGY CORPORATION (US) | 1995-10-03 | — | — | US | disclosed |
| US-5451700-A | Leukotriene inhibitors | CIBA-GEIGY CORPORATION (US) | 1995-09-19 | — | — | US | disclosed |
| EP-0669909-A1 | SUBSTITUTED AMIDINO COMPOUNDS, THEIR MANUFACTURE AND METHODS OF TREATMENT | Novartis AG (CH) | 1995-09-06 | — | — | EP | disclosed |
| EP-0518819-B1 | Amidino compounds, their manufacture and use as medicament | CIBA GEIGY AG (CH) | 1995-08-02 | — | — | EP | disclosed |
| EP-0601977-A1 | Aromatic hydroxyamidine derivatives and their use as leukotriene B4 receptor anagonists | CIBA-GEIGY AG (CH) | 1994-06-15 | — | — | EP | disclosed |
| WO-1994011341-A1 | SUBSTITUTED AMIDINO COMPOUNDS, THEIR MANUFACTURE AND METHODS OF TREATMENT | CIBA-GEIGY AG (CH) | 1994-05-26 | — | — | WO | disclosed |
| US-5246965-A | Leukotriene antagonist | CIBA-GEIGY (US) | 1993-09-21 | — | — | US | disclosed |
| EP-0518818-A2 | Arylethers, their manufacture and use as medicament | CIBA-GEIGY AG (CH) | 1992-12-16 | — | — | EP | disclosed |
| EP-0518819-A2 | Amidino compounds, their manufacture and use as medicament | CIBA-GEIGY AG (CH) | 1992-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | CBR1, CBR3, QSOX1 | SMN1; SMN2 2152/4885HIF1A 1390/4885SLC6A2 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.